The global pain management devices market size was estimated at USD 6.92 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 9.5% from 2023 to 2030. The growing prevalence of chronic conditions is one of the key aspects anticipated to contribute to the market's growth during the forecast period. The increasing prevalence of lifestyle diseases, such as diabetes and obesity, has boosted the demand for nerve and muscle stimulators. The rising prevalence of hypertension or trauma is another significant factor expected to propel market growth. Hypertension significantly raises the risk of chronic conditions, such as brain aneurysms. According to the World Health Organization (WHO) data released on March 16, 2023, approximately 1.28 billion adults aged 30 to 79 years globally are affected by hypertension.
The COVID-19 pandemic had economic implications and impact on most sectors, including the medical device market. The national lockdown has affected patients who especially depended on PT or exercise programs as a pain management technique. Furthermore, numerous in-person patient visits and elective practices have been delayed or suspended, which is anticipated to augment the need for pain treatment at home. In December 2022, Abbott introduced the world's smallest, rechargeable, implantable spinal cord stimulation system - FDA approved Eterna Spinal Cord Stimulation (SCS) system for chronic pain treatment.The growing number of cancer cases is anticipated to further boost the demand during the forecast period.
In addition, rolling issues of musculoskeletal conditions, such as osteoarthritis, orthopedic degenerative diseases, arthritis, and rheumatoid arthritis, are rising significantly. This has increased the prevalence of chronic pain in these people and the incapability to carry out everyday chores. For instance, according to the Centers for Disease Prevalence and Control (CDC), over 58.5 million adults in the U.S. have arthritis. The CDC expected around 35 million individuals to be limited in their usual activities because of arthritis by 2040. This has propelled the market for pain management stimulators to control chronic pain. In addition, an upsurge in the number of accident cases, obesity, bone-related diseases, and the comfort of advanced procedures are also anticipated to promote market expansion. Obesity is the primary cause of arthritis.
According to an article by Paras Health in April 2022, being overweight or obese and having a BMI of more than 30 increased the chance of joint pain by 60% compared to normal weight. Every pound of extra weight exerts nearly 4 pounds of additional pressure on the knees.The inefficacy of oral drugs is encouraging patients to look for other available treatment alternatives, such as pain control devices. Many individuals are addicted to painkillers. However, these medications show side effects and are sometimes inefficient. Furthermore, the lack of choice options for surgeries is one of the aspects increasing the demand.
According to the 2021 National and State Healthcare-Associated Infections (HAIs) Progress Report, SurgicalSite Infections (SSI) with abdominal hysterectomy (HYST) increased by around 11% over the first and second years of the COVID-19 pandemic. The increased hospitalization expenses have boosted the need for shorter hospital stays and affordable care settings, thus growing the market demand. For instance, according to the article by Debt.Org, LLC published in March 2023, The average daily cost of hospitalization in the U.S. is approximately USD 2,883, and the average length of a hospital stay is about 4.6 days, resulting in an average total expense of USD 13,262.
Technological advances are also expected to propel market growth. For instance, in January 2021, in the U.S., Boston Scientific Corporation introduced WaveWriter Alpha Spinal Cord Stimulator Systems. It is developed to offer deep paresthesia-free pain comfort in minutes. In February 2022, Boston Scientific Corporation acquired Baylis Medical Company, Inc. This acquisition extended Boston Scientific's electrophysiology product and structural heart portfolios, including the VersaCross Transseptal and radiofrequency NRG Platforms and dilators utilized to allow left heart access.
Based on products, the market is segmented into radiofrequency ablation, electrical stimulators, analgesic infusion pump, and neurostimulation. Neurostimulation products held the largest revenue share of 57.7% in 2022. The dominance can be attributed to the rise in the cases of neurological diseases. These neurostimulators are essential in treating Parkinson’s, epilepsy, chronic pain, movement diseases, and depression. Moreover, factors, such as the launch of cutting-edge products, growing product demand, and the rising geriatric population, are expected to drive the market.
For example, according to the UK government, the population within the age group of 70 to 74 years increased from 3,252 in 2018 to 3,390 in 2021. The growing aging population is projected to propel the market, as the aged population is at a tremendous risk of chronic disease.Radiofrequency Ablation (RFA) is anticipated to exhibit the fastest CAGR of 9.7% during the forecast period owing to its vast application in pain management, gynecology, surgical oncology, cosmetology, cardiology & cardiac rhythm management. Radiofrequency ablation treatment is more helpful in treating patients with numerous tumors than patients via open surgery, thus boosting segment growth.
Based on application, the market is segmented into cancer, facial & migraine, neuropathic pain, musculoskeletal condition, trauma & others, etc. The neuropathic pain segment held the largest revenue share of around 31.9% in 2022. The dominance can be attributed to the growing initiatives by the industry players and the rising prevalence of the target individuals. According to the article by Boston Scientific Corporation published in January 2021, over 50 million individuals in the U.S. suffer chronic pain, and around 19.6 million adults in the U.S. experience high-impact chronic pain that hinders everyday work or life activities. The factors mentioned above are anticipated to fuel growth.
The cancer segment is anticipated to grow at the fastest CAGR of 10.0% during the forecast period. The growing number of cancer patients has augmented the need for pain management devices to alleviate the pain caused owing to nerve compression, primarily because of the tumor compressing and other variables relying upon cancer’s advancement. In addition, most genetic disorders, such as Acute Lymphoblastic Leukemia (ALL), are projected to propel the market demand over the forecast period. According to the study published by the Indian Journal of Medical Research in November 2022, around 14,61,427 cancer cases were found in India in 2022. Approximately 1 in 9 individuals are at risk of developing cancer in their lifetime.
North America held the largest revenue share of 46.3% in 2022 owing to the advanced healthcare infrastructure enabling easy access to cutting-edge pain management devices. In addition, rising government initiatives and schemes, such as the Precision Medicine and Affordable Care Act, coupled with a well-planned reimbursement scheme in this area, are enhancing the market demand.The regional market is driven by factors, such as the presence of established healthcare facilities, a growing geriatric population, and a high prevalence of stroke & hypertension. With the increasing number of older adults, the market is expected to demonstrate a higher growth rate as this demographic is more susceptible to chronic conditions.
According to the Australian Institute of Health and Welfare, chronic musculoskeletal ailments impact about 30% population of Australia.Furthermore, the presence of key companies in the region including Boston Scientific Corp., Medtronic, Baxter International Inc., Abbott, and Stryker Corp., supports market growth. These players undertake various strategic initiatives to gain higher industry shares. The Asia Pacific region is expected to grow at an attractive CAGR of 11.1% over the forecast period owing to R&D investments to build technologically developed healthcare treatment alternatives.
To gain deeper penetration, the players are frequently undertaking strategic initiatives, such as partnerships, regional expansion, technology innovation, and mergers and acquisitions. For instance, in January 2022, Medtronic plc, a company in healthcare technology, declared that it had obtained the U.S. Food and Drug Administration (FDA) approval for its Vanta neurostimulator, which is recharge-free and Intellis neurostimulator, which is rechargeable to treat regular pain associated with Diabetic Peripheral Neuropathy (DPN). Some of the prominent players in the global pain management devices market are:
B. Braun Melsungen AG
Boston Scientific Corp.
OMRON Healthcare, Inc.
The market size value in 2023
USD 7.49 billion
The revenue forecast in 2030
USD 14.14 billion
CAGR of 9.5% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; Germany; UK; France; Italy; Spain;The Netherlands; Japan; China; India; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia
Key companies profiled
B. Braun Melsungen AG; Baxte; Boston Scientific Corp.; Enovis; Medtronic; ICU Medical, Inc.; Abbott; Stryker; Nevro Corp.; Omron Healthcare, Inc.; Stimwave LLC
Free report customization (equivalent up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the pain management devices market based on product, application, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Radiofrequency Ablation (RFA)
Analgesic Infusion Pumps
Intrathecal Infusion Pumps
External Infusion Pumps
Spinal Cord Stimulators
Deep Brain Stimulators
Application Outlook (Revenue, USD Million, 2018 - 2030)
Facial & Migraine
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global pain management devices market size was estimated at USD 6.92 billion in 2022 and is expected to reach USD 7.49 billion in 2023.
b. The global pain management devices market is expected to grow at a compound annual growth rate of 9.5% from 2023 to 2030 to reach USD 14.14 billion by 2030.
b. North America dominated the pain management devices market with a share of over 46.0% in 2022. This is attributable to favorable healthcare infrastructure, government initiatives, and well-planned reimbursement policies.
b. Some key players operating in the pain management devices market include B Braun Melsungen AG; Baxter International, Inc.; Boston Scientific Corp.; Codman and Shurtleff; DJO Global LLC; Pfizer, Inc.; Medtronic Plc; Smiths Medical; St. Jude Medical, Inc.; and Stryker Corp.
b. Key factors that are driving the pain management devices market growth include the high prevalence of diabetes, rising geriatric population base, and increasing cases of cancer.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."